tbuckley/cabot-search huggingface dataset:
THE LIBRARY OF THE SURGEON-GENERAL'S OFFICE.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Council on Pharmacy and Chemistry
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12–17 Years — United States, December 9, 2021–February 20, 2022
Authors: Anne M. Hause, James Baggs, Paige Marquez, Winston E. Abara, Babatunde Olubajo, Tanya R. Myers, John R. Su, Deborah Thompson, Julianne Gee, Tom T. Shimabukuro, David K. Shay
Journal: MMWR Morbidity and Mortality Weekly Report (2022)

As of February 20, 2022, only BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine has been authorized for use in persons aged 12-17 years in the United States (1). The Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for Pfizer-BioNTech vaccine on December 9, 2021, to authorize a homologous* booster dose for persons aged 16-17 years ≥6 months after receipt of dose 2 (1). On January 3, 2022, authorization was expanded to include persons aged 12-15 years, and for all persons aged ≥12 years, the interval between dose 2 and booster dose was shortened to ≥5 months (1). To characterize the safety of Pfizer-BioNTech booster doses among persons aged 12-17 years (adolescents), CDC reviewed adverse events and health impact assessments during the week after receipt of a homologous Pfizer-BioNTech booster dose reported to v-safe, a voluntary smartphone-based safety surveillance system for adverse events after COVID-19 vaccination, and adverse events reported to the Vaccine Adverse Event Reporting System (VAERS), a passive vaccine safety surveillance system managed by CDC and FDA. During December 9, 2021-February 20, 2022, approximately 2.8 million U.S. adolescents received a Pfizer-BioNTech booster dose.† During this period, receipt of 3,418 Pfizer-BioNTech booster doses were reported to v-safe for adolescents. Reactions were reported to v-safe with equal or slightly higher frequency after receipt of a booster dose than after dose 2, were primarily mild to moderate in severity, and were most frequently reported the day after vaccination. VAERS received 914 reports of adverse events after Pfizer-BioNTech booster dose vaccination of adolescents; 837 (91.6%) were nonserious and 77 (8.4%) were serious. Health care providers, parents, and adolescents should be advised that local and systemic reactions are expected among adolescents after homologous Pfizer-BioNTech booster vaccination, and that serious adverse events are rare.
Tranquilizer Control
Authors: Arthur Kaufman
Journal: JAMA (1973)

<h3>To the Editor.—</h3> We read with pleasure, and then dismay, the letter by Blackwell (223:798, 1973) concerning our article on tranquilizer control in a clinic population (221:1504, 1972). Dr. Blackwell fears the void created by our diminished prescribing of minor tranquilizers may have been filled by increased prescribing of barbiturates and phenothiazines. There was no such increase in our study. Prescriptions for phenobarbital, the only barbiturate prescribed with any frequency, declined by approximately two thirds. Dr. Blackwell's concern that our patients may be driven to seek the same drugs outside the clinic or resort to increased use of alcohol is well taken. It was for this reason that we tried to substitute counseling for tranquilizers and mailed appeals and information packets to all other physicians in our community. Further, a proposal for an alcohol treatment program submitted at the time of the study was recently funded and has begun operation
蜂窝组织炎试验中报告哪些成果?蜂窝组织炎试验和患者优先级设置调查成果的评述结果
Authors: E. Smith, M. Patel, K. S. Thomas
Journal: British Journal of Dermatology (2018)

蜂窝组织炎是具有潜在严重性的皮肤组织细菌感染,通常发生在小腿部位。除了短期迹象和症状外,这种疾病还会对患者生理和心理健康造成长期的严重影响。蜂窝组织炎还会对健康服务构成巨大负担;例外英国在2014至2015年共有114190名患者入院接受蜂窝组织炎治疗,住院时长中位数为6天。目前所认识到的是,临床试验的很多成果(即试验所寻求的结果)因具体试验而异,难以对比不同试验的结果。因此,研发试验核心成果集合(COS)会有帮助。COS是一套约定的成果,是特定医疗领域的所有临床试验必须衡量和报告的结果。研发核心成果集合的初期旨在确定有哪些成果以及对医疗用户最重要、最相关的成果。这份来自英国的评述旨在描述随机对照试验(RCT)中报告的与治疗和预防蜂窝组织炎相关的所有成果指标。最终分析包含48项试验,每项试验有一到八个成果指标。本研究的第二个目标是确定蜂窝组织炎优先级设置合作计划(PSP)的患者和医疗专业人士反馈中的成果主题。优先级设置合作计划有助于汇集患者、护理人员和临床医生,为研究确定其认为最重要的治疗不确定性并进行优先排序。防止复发是患者和医疗专业人士最常提到的重要成果主题。“以治疗为主”的成果(如抗菌治疗时长)也是医疗专业人士重点关注的成果,而临床特征(最常见的是红斑、肿胀和疼痛)的评估则是患者第二看重的成果。出乎意料的是,只有2%的成果主题关注生活质量和治疗满意度。作者们得出结论,蜂窝组织炎的成果指标不应具有一致性,好让临床试验能够充分对比,而是应该反映对患者日常生活的实际影响。
Nephrotic syndrome associated with congenital syphilis
Authors: P. Pollner
Journal: JAMA (1966)

Congenital syphilis is a rare but definite cause of the nephrotic syndrome. The lesion has not been previously reported in patients with the acute form of the disease and only recently has been demonstrated in patients with acquired syphilis. Renal alterations demonstrated by open kidney biopsy in a patient with congenital syphilis and the nephrotic syndrome were compatible with those seen in patients with membranous glomerulonephritis and in patients with the acquired form of the disease.
Complicated rheumatoid disease.
Journal: BMJ (1966)

Complicated Rheumatoid DiseaseThe term " rheumatoid disease " was first used by P. Eliman and R. E. Ball' to indicate that the morbid process of rheumatoid arthritis is not confined to the joints.Now, nearly 20 years later, Dr. F. Dudley Hart shows in his Edgecombe lecture, published at page 131 of the B.M.7.this week, how time has supported this concept.
Krebsverbreitung, Krebsbekämpfung, Kregsverhütung.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BTS Clinical Statement on air travel for passengers with respiratory disease
Authors: Robina Kate Coker, Alison Armstrong, Alistair Colin Church, Steve Holmes, Jonathan Naylor, Katharine Pike, Peter Saunders, Kristofer John Spurling, Pamela Vaughn
Journal: Thorax (2022)

The Statement addresses adults and children with the following conditions or undergoing the following procedures: ► Airflow obstruction including asthma and COPD.► Bronchopulmonary dysplasia.► Cystic fibrosis (CF).► Non-CF bronchiectasis.► Restrictive respiratory disease including interstitial lung disease (ILD), respiratory muscle and chest wall disorders.► Thoracic surgery or other interventional procedures.► Pleural disease including pneumothorax and pleural effusion.► Respiratory infections.► Obstructive sleep apnoea syndrome (OSAS) and obesity hypoventilation syndrome (OHS).► Venous thromboembolism (VTE).► Pulmonary hypertension (PH).► Lung cancer and mesothelioma.► Hyperventilation and dysfunctional breathing (DB).Preflight assessment is described.Appendix A provides information on logistics for air travel with equipment (nebulisers, oxygen and ventilators); Appendix B provides technical information for respiratory physiologists.Sources of useful information, Information for primary care healthcare practitioners and for patients are provided in online supplemental appendices 1-3.Heart disease and HIV are excluded, as are emergency repatriation and travel on military or other non-commercial flights including helicopter travel.The Terrence Higgins Trust and British Heart Foundation provide advice on travel with HIV and heart conditions respectively (see online supplemental appendix 1). METHODOLOGYDr Robina Coker chaired the clinical statement group (CSG).Membership was drawn from respiratory medicine, paediatrics, nursing, respiratory physiology, physiotherapy and primary care.The CSG identified key areas requiring Clinical Practice Points.The group reviewed previous BTS recommendations on this topic 1-3 and supplemented the evidence with up-to-date literature searches.The overall content was developed to reflect the scope approved by the BTS Standards of Care Committee (SOCC).Following discussions of broad statement content, individual sections were drafted by group members.
Who Gets Pneumonia after Surgery?
Journal: Annals of Internal Medicine (2001)

Summaries for Patients20 November 2001Who Gets Pneumonia after Surgery?Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-10-200111200-00001 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Pneumonia (infection of the lung tissue) is a serious complication that sometimes occurs after major surgery. It causes such symptoms as fever, shortness of breath, cough, and chest pain. It often requires treatment with antibiotics and lengthens the time until the patient is well enough to leave the hospital. Pneumonia after surgery is a very serious problem because 20% to 40% of affected patients die within 30 days of surgery. If physicians knew which patients are most likely to get pneumonia after surgery, they could target efforts to ... Author, Article, and Disclosure InformationAffiliations: The summary below is from the full report titled “Development and Validation of a Multifactorial Risk Index for Predicting Postoperative Pneumonia after Major Noncardiac Surgery.” It is in the 20 November 2001 issue of Annals of Internal Medicine (volume 135, pages 847–857). The authors are AM Arozullah, SF Khuri, WG Henderson, J Daley, and the participants in the National Veterans Affairs Surgical Quality Improvement Program.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoDevelopment and Validation of a Multifactorial Risk Index for Predicting Postoperative Pneumonia after Major Noncardiac Surgery Ahsan M. Arozullah , Shukri F. Khuri , William G. Henderson , Jennifer Daley , and Metrics Cited byPreoperative predictors of increased hospital costs in elective anterior cervical fusions: a single-institution analysis of 1,082 patientsAdvanced age is an independent predictor for increased morbidity and mortality after emergent surgery for diverticulitisOutcomes of damage-control celiotomy in elderly nontrauma patients with intra-abdominal catastrophes 20 November 2001Volume 135, Issue 10Page: I-54KeywordsCardiac surgeryChartsLungsMedical risk factorsPneumoniaStrokeSurgeryThoracic surgeryThoraxWeight loss ePublished: 20 November 2001 Issue Published: 20 November 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Correction
Journal: BMJ (1960)

BRITISHgives the clue, as in an adult developing meningo-encephalitis in a family in which a child had recently had parotitis.The course of the disease is usually relatively mild, but sometimes the patient is comatose.Recovery is usually obvious after a few days to a week and the patient is well within a fortnight.There is no specific treatment.Cortisone has been used, but with doubtful success2: since spontaneous recovery is the rule, there seems no need to use it except in unusually severe cases.
Hiatus hernia and reflux esophagitis.
Authors: Briti Sh
Journal: BMJ (1969)

PointersCancer Therapy: Good results from preliminary trial of treating acute lymphoblastic leukaemia with active immunotherapy reported by Professor Georges Math6 (p. 7).Renal Disease: Serial determinations of endo- genous creatinine clearance particularly valuable in assessing changing glomerular filtration rates (p.11).Tropical Splenomegaly: No immunological deficiency found in eight patients studied in Uganda (p.15).Leader at p. 4. Fetal Blood Glucose: Level found to be dependent on maternal blood glucose concentration.Insulin in fetus may have a role in anabolism rather than in control of fetal glucose level (p.17).
Mr E J Greenwood
Journal: BMJ (1979)

to judge the validity of his hypotheses, but if proved correct they will greatly clarify the basis of the physical treatment of psychiatric disorders.His routine work in the hospital displayed the same thorough probing attitude toward every clinical problem that came his way.He was a quiet man, unobtrusively kind, and his politeness and reserve largely concealed his considerable erudition.During his years at Stone House Hospital he carried a heavy burden of medical administrative responsi- bility and worked ceaselessly to improve the psychiatric facilities for the people of Graves- end.His efforts met with much frustration and delay, which he accepted with characteristic patience and wry humour.It is intended that
ORGANIZATION SECTION
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Skilled Nursing Facility Performance and Readmission Rates Under Value-Based Purchasing
Authors: Robert E. Burke, Yao Xu, Liam Rose
Journal: JAMA Network Open (2022)

The new Medicare Skilled Nursing Facility Value-Based Purchasing program (SNF VBP) seeks to improve patient outcomes by awarding financial incentives or penalties based on 30-day hospital readmission rates. Skilled nursing facilities (SNFs) can avoid a penalty through low baseline readmission rates or improvement over time.To assess the baseline performance and improvement over time of SNFs in the SNF VBP program.This cross-sectional study examined readmission rates, financial penalties and incentives, and facility and patient characteristics associated with these outcomes at 14 959 US SNFs that received Medicare payments between January 1, 2015, and December 31, 2019.Outcomes were readmission rates and financial penalties by facility. The SNFs were classified as improvers in the analysis if they had better improvement scores than baseline scores under the program and achievers if they had higher baseline scores than improvement scores.Of 14 959 SNFs studied, 1849 (12.3%) were assigned their improvement score as their performance score in the first year of the program. Of these, 1167 (63.1%) received a financial penalty, whereas 374 (20.2%) received a bonus. Only 52 facilities that performed poorly at baseline (0.3% of all SNFs and 0.7% of below-median performers) were able to improve enough to avoid a financial penalty, despite large improvements in readmission rates. Improver SNFs treated larger racial minority populations (mean [SD], 74.57% [23.42%] White in the improver group vs 79.15% [22.18%] in the achiever group) and were located in counties with larger minority populations (mean [SD], 15.48% [14.05%] Black in the improver group vs 11.57% [12.72%] Black in the achiever group). The most important predictors of improvement were related to SNF finances, such as operating margin (mean [SD], -0.74 [13.87]) and occupancy rates (mean [SD], 79.93 [14.81]).This cross-sectional study suggests that the SNF VBP program did not offer a viable path for nearly all low-performing SNFs to avoid financial penalties through improved readmission rates.
Queries and Minor Notes.
Journal: JAMA (1903)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of obesity in children
Authors: A. J. Stunkard
Journal: JAMA (1990)

Two propositions about obesity are generally accepted: fat children grow into fat adults,<sup>1,2</sup>and weight lost in treatment programs is promptly regained.<sup>3</sup> It is against this background that the 10-year follow-up of treatment of obese children, reported by Epstein and colleagues<sup>4</sup>in this issue ofThe Journal, must be considered. For this study showed that obese children treated for a very short period of time (eight weekly meetings followed by six monthly meetings) showed effects of treatment 10 years later, when they were significantly less obese than children in a comparison group. How are we to explain these surprising results? Three possible explanations seem unlikely. Differential attrition between treatment and control groups is always a possibility in long-term follow-up studies, and there was some attrition in this study. The attrition, however, was limited—only 14 of 75 children became unavailable for follow-up—and it was distributed about evenly among